- Patients, who eligible to sign informed consent;
- Patients with indications to lipid lowing therapy, according to local product
- Patients with CHD and high risk of CV complications (Diabetes Mellitus II, Myocardial
Infarction, Heart Failure, Arterial Hypertension, ets) will be included into study;
- Patients with LDL levels: > 3,5 mmol/l
- Individual intolerance of atorvastatin, in accordance to local product document.